QuidelOrtho Formed by Combining Quidel and Ortho

 In December 2021, Quidel acquired Ortho in a USD 6 billion transaction that aims to unite technologies and platforms to offer expanded access to clinical chemistry, immunoassay, molecular diagnostics, immunohematology, donor screening and point-of-care diagnostic offerings. 

QuidelOrtho’s comprehensive product portfolio covers a wide range of point-of-care tests for infectious diseases, critical cardiac health and autoimmune biomarkers, and a host of clinical and at-home products to detect COVID-19. QuidelOrtho’s core competencies and capabilities include immunoassay development, automated manufacturing, monoclonal antibody characterization and development, molecular assay development, lab-based in vitro diagnostics, blood bank solutions and transfusion pre-screening.

QuidelOrtho’s current products fall generally into these categories: (1) visually-read lateral flow, with expertise in infectious disease and reproductive health; (2) direct fluorescent antibodies (DFA), with expertise in infectious disease and virology; (3) micro-titer production, with a focus on bone and complement pathway markets; (4) fluorescent immunoassay products (Sofia); (5) molecular diagnostic products including the flagship Savanna, an integrated molecular diagnostic system; (6) immunodiagnostics, clinical chemistry and integrated testing systems to serve diagnostic labs of all sizes (VITROS Systems); (7) immunodiagnostic donor screening systems and services that drive blood safety (Ortho Summit/VERSEIA/VITROS Systems); (8) pre-transfusion testing that automates blood bank workload (VITROS 3600) with software to standardize operations, simplify tasks, and improve productivity (ORTHO CONNECT); and (9) a combination of service, expertise, technology and data-driven solutions to drive effective, efficient labs (Ortho Care Services & Informatics).

“We are very excited to bring together the talented and experienced teams of both Quidel and Ortho who share a commitment to the employees, customers, patients, and the communities we serve,” said Douglas Bryant, Chairman and Chief Executive Officer of QuidelOrtho. “There is a lot of important work ahead of us to deliver on our targeted synergies and new product introductions and we are energized and poised to excel in our combined mission to deliver advanced diagnostics to improve human health.”

Related Links:
QuidelOrtho Corporation 
Quidel Corporation 
Ortho Clinical Diagnostics